Orthopedic Products

Cingal is the first and only CE-marked combination product designed to deliver the benefits of cross-linked hyaluronic acid (HA) alongside a fast-acting steroid. This innovative single-injection treatment merges Anika’s proprietary HA formulation with a corticosteroid, offering effective relief from osteoarthritis (OA) symptoms. It provides rapid pain relief that lasts up to six months.

SUPARTZ is indicated for the treatment of knee osteoarthritis and periarthritis of the shoulder. It is a sterile, non-pyrogenic solution of highly purified, non-inflammatory, high molecular weight sodium hyaluronate, derived from chicken combs. This polysaccharide consists of repeating disaccharide units of D-glucuronic acid and N-acetyl-D-glucosamine.

SUPARTZ is provided sterile in a single-use, pre-filled disposable syringe to minimize the risk of contamination during the aspiration of the solution.

MONOVISC is a single-injection treatment designed to relieve knee pain caused by osteoarthritis (OA). It is intended for patients who have not responded to simple analgesics or conservative non-pharmacologic therapy.

SUPARTZ is indicated for the treatment of knee osteoarthritis and periarthritis of the shoulder. It is a sterile, non-pyrogenic solution of highly purified, non-inflammatory, high molecular weight sodium hyaluronate, derived from chicken combs. This polysaccharide consists of repeating disaccharide units of D-glucuronic acid and N-acetyl-D-glucosamine.

SUPARTZ is provided sterile in a single-use, pre-filled disposable syringe to minimize the risk of contamination during the aspiration of the solution.

Synvisc (hylan G-F 20) is a viscosupplement injection used to supplement the natural fluid in the knee, helping to lubricate and cushion the joint. It works by restoring the joint’s elasticity and viscosity, which enhances mobility and provides relief from osteoarthritis-related knee pain.

Synvisc-One is a single-dose injection designed to relieve knee pain caused by osteoarthritis (OA). It works by restoring the knee joint’s elasticity and viscosity, allowing for improved movement. Additionally, Synvisc-One supplements the joint fluid, providing lubrication and cushioning for better comfort and function.

Synvisc-One is indicated for patients with OA-related knee pain who have not responded adequately to conservative non-pharmacologic therapy or simple analgesics, such as acetaminophen.

Euflexxa is an injectable treatment designed to relieve knee pain caused by osteoarthritis, particularly in patients who have not responded to other therapies such as acetaminophen, exercise, or physical therapy. Clinical studies have shown that Euflexxa can provide pain relief for up to six months.

Euflexxa (1% sodium hyaluronate) is a substance similar to the natural fluid that surrounds the surfaces of joints. This fluid functions as a lubricant and shock absorber. When Euflexxa is injected into the knee, it helps replace the body’s natural hyaluronic acid that has been lost due to osteoarthritis, thereby reducing pain and improving joint function. The hyaluronic acid used in Euflexxa is non-animal derived and is purified through a multistep filtration process, making the treatment both safe and effective.

It is important that Euflexxa is administered on a proper schedule. The full therapeutic effect may take up to three injections to be achieved.

Hyalgan 20 mg/2 ml is a solution for intra-articular injection presented in a pre-filled syringe. It belongs to the pharmacotherapeutic class of other drugs for musculoskeletal disorders. This medication is used to treat painful osteoarthritis of the knee accompanied by joint effusion.

Hyalgan provides relief by supplementing the natural synovial fluid in the joint, improving lubrication and cushioning. Its therapeutic effect is not immediate, with maximum pain reduction typically occurring two to three months after the first injection.

Hymovis is an injectable gel developed to treat knee pain associated with osteoarthritis. It is made from a proprietary, highly modified form of hyaluronan, which offers enhanced lubrication and shock absorption within the joint. This advanced formulation helps restore joint function and provides long-lasting pain relief. Hymovis is administered in a convenient two-injection regimen and is manufactured by Fidia.

Orthovisc is an ultra-pure, high molecular weight injectable hyaluronic acid (HA) viscosupplement designed to relieve joint pain caused by osteoarthritis. It contains highly purified sodium hyaluronate (NaHA) suspended in physiologic saline, making it both biocompatible and resorbable.

Orthovisc helps reduce joint pain and improve mobility, with results that can last up to 26 weeks. It is formulated with natural, non-animal sourced HA, and has shown no confirmed pseudoseptic reactions in clinical studies.